Publication details

Indikace PCSK9 inhibitorů v nové léčbě hypercholesterolémie v zorném poli ČSAT

Title in English Indications of the PCSK9 inhibitors in the treatment of hypercholesterolemia in a new field of vision of the Czech atherosclerosis society
Authors

SOŠKA Vladimír VRABLÍK Michal BLÁHA Vladimír CÍFKOVÁ Renata ČEŠKA Richard FREIBERGER T. KRAML Pavel PIŤHA Jan ROSOLOVÁ Hana ŠTULC Tomáš VEVERKOVÁ Helena URBANOVÁ Zuzana

Year of publication 2016
Type Article in Periodical
Magazine / Source Hypertenze & kardiovaskulární prevence
MU Faculty or unit

Faculty of Medicine

Citation
Field Cardiovascular diseases incl. cardiosurgery
Keywords familial hypercholesterolemia; statins; PCSK9 inhibitors; LDL-cholesterol
Description First line drug for the treatment of hypercholesterolemia are statins, which reduce LDL-cholesterol up to 50 %; such reduction is sufficient for most patients to achieve the target values. The exceptions are patients with familial hypercholesterolemia and patients with statin intolerance. To achieve target LDL-cholesterol in these two groups of patients will be possible with new drugs – PCSK9 inhibitors, which decrease LDL-cholesterol by an additional 50–60 %. The first two PCSK9 inhibitors (alirocumab and evolocumab) already had been approved for clinical use by European regulatory authorities. The primary indication for combination statin with PCSK9 inhibitor should be undoubtedly patients with a confirmed diagnosis of familial hypercholesterolemia, who are treated in the Czech Republic primarily in specialized centers of MedPed project. Furthermore, this treatment should be available for other patients at very high risk of cardiovascular diseases, who cannot achieve target LDL-cholesterol (eg. for statins intolerance).

You are running an old browser version. We recommend updating your browser to its latest version.

More info